Immunotherapy is not only significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), but actually appears to fuel tumor growth, according to a Mount ...
Mar 24, 2021
0
63
National University of Singapore researchers have discovered that the MOAP-1 protein plays a role in reducing liver cancer risk by suppressing the hyper-active cancer-promoting Nrf2 cellular signaling pathway.
Feb 5, 2021
1
113
Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant ...
Jan 19, 2021
0
70
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...
Mar 21, 2018
0
1420
Adoptive cell-therapies, in which a patient's own immune cells are used to recognize and target tumors, have shown breakthrough results for patients with certain B-cell malignancies, or cancers of the blood, but this therapy ...
Sep 14, 2016
0
115
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data ...
Jan 30, 2014
0
0
Among patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (development of excess fibrous connective tissue), sustained virological response (SVR) to interferon-based treatment was associated with ...
Dec 25, 2012
0
0
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer worldwide but is often diagnosed at an advanced incurable stage. Yet, despite the urgent need for blood-based biomarkers for early detection, ...
Feb 12, 2024
0
0
Hepatocellular carcinoma (HCC) is a common human disease and one of the main causes of cancer-related death. The angiogenesis inhibitor Sorafenib (SORA) is commonly used in the treatment of advanced HCC as a first-line drug.
Feb 7, 2024
0
0
More than two-thirds of patients with hepatocellular carcinoma (HCC) who receive surgical interventions experience recurrence owing to lack of an established perioperative treatment. Now, researchers from Korea University ...
Feb 6, 2024
0
0
